LIN BIOSCIENCE, INC.
Area: Government, Academia and Research Institutes
Booth No: M434
Website: https://www.linbioscience.com/tw/
Exhibitor Profile
Lin BioScience, Inc. (TPEx: 6696), established in 2016, is a drug development company advancing novel therapies and first-in-class treatments for unmet medical needs in ophthalmology, oncology and metabolic diseases. Its pipeline includes four candidate drugs: LBS-008 for dry AMD and STGD1, and LBS-009 for NASH, developed by its subsidiary Belite Bio Inc. (Nasdaq: BLTE); and LBS-007 for acute leukemias and solid tumors, and LBS-002 for glioblastoma and metastasis, developed by Lin BioScience.
Brands
Lin BioScience (LBS-007)、Belite Bio (LBS-008 / Tinlarebant)
Exhibit Products
Exhibitors you may be interested in
Highest Rated